French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
Radiopharma startup Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Ther